Orum Therapeutics, Inc. Logo

Orum Therapeutics, Inc.

Clinical-stage biotech developing degrader-antibody conjugates to treat cancer.

475830 | KO

Overview

Corporate Details

ISIN(s):
KR7475830006
LEI:
Country:
South Korea
Address:
대전광역시 유성구 문지로 281-25, 대전광역시

Description

Orum Therapeutics is a clinical-stage biotechnology company that develops targeted protein degradation (TPD) therapeutics. The company's proprietary TPD²® platform creates a novel class of antibody-drug conjugates (ADCs), referred to as degrader-antibody conjugates (DACs). This technology combines the cell-targeting precision of antibodies with the catalytic action of protein degraders. The approach is designed to selectively deliver payloads to diseased cells to eliminate intracellular proteins that are difficult to target with conventional drugs. Orum's primary focus is on developing treatments for cancer, aiming to improve efficacy and safety over existing therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-16 00:00
주식등의대량보유상황보고서(일반)
Korean 352.9 KB
2025-08-29 00:00
주식등의대량보유상황보고서(일반)
Korean 348.3 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-08 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 382.4 KB
2025-08-08 00:00
주식등의대량보유상황보고서(일반)
Korean 339.8 KB
2025-08-01 00:00
임시주주총회결과
Korean 10.7 KB
2025-08-01 00:00
주식매수선택권부여에관한신고
Korean 21.5 KB
2025-07-25 00:00
주식등의대량보유상황보고서(일반)
Korean 368.6 KB
2025-07-17 00:00
주주총회소집공고
Korean 77.7 KB
2025-07-10 00:00
[기재정정]주주총회소집결의
Korean 16.8 KB
2025-06-25 00:00
주주총회소집결의
Korean 10.7 KB
2025-06-25 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.2 KB
2025-06-04 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 372.2 KB
2025-06-04 00:00
[기재정정]주식등의대량보유상황보고서(일반)
Korean 360.6 KB
2025-05-26 00:00
기업설명회(IR)개최
Korean 6.7 KB

Automate Your Workflow. Get a real-time feed of all Orum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Orum Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Orum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

genOway Logo
Designs and develops genetically modified preclinical models for research.
France
ALGEN
Genprex, Inc. Logo
Clinical-stage gene therapy company developing therapies for cancer and diabetes.
United States of America
GNPX
Genxone Spolka Akcyjna Logo
A biotechnology company specializing in Next Generation Sequencing and medical diagnostics.
Poland
GX1
GeoVax Labs, Inc. Logo
Clinical-stage biotech developing vaccines and therapies for infectious diseases and cancer.
United States of America
GOVX
GH Research PLC Logo
Develops mebufotenin-based therapies for psychiatric and neurological disorders.
United States of America
GHRS
GI Innovation Inc. Logo
Researches and develops protein-based drugs for immuno-oncology and immunology.
South Korea
358570
Ginkgo Bioworks Holdings, Inc. Logo
Operates a horizontal platform for cell programming and synthetic biology.
United States of America
DNA
GRAIL, Inc. Logo
A healthcare company developing blood tests for multi-cancer early detection.
United States of America
GRAL
GT Biopharma, Inc. Logo
Clinical-stage immuno-oncology company developing therapies with its NK cell engager tech.
United States of America
GTBP
Guard Therapeutics International AB Logo
Clinical-stage biotech developing therapies to prevent acute kidney injury.
Sweden
GUARD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.